Anne-Sophie Hamy1,2, Hélène Bonsang-Kitzis1,3, Marick Laé4, Fabien Reyal5,3,6, Diane De Croze7, Enora Laas3, Lauren Darrigues3, Lucian Topciu4, Emmanuelle Menet7, Anne Vincent-Salomon4, Florence Lerebours8, Jean-Yves Pierga2,6, Etienne Brain8, Jean-Guillaume Feron3, Gabriel Benchimol3, Giang-Thanh Lam3,9. 1. Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France. 2. Department of Medical Oncology, Institut Curie, Paris, France. 3. Department of Surgery, Institut Curie, Paris, France. 4. Department of Tumor Biology, Institut Curie, Paris, France. 5. Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France. fabien.reyal@curie.fr. 6. Université Paris, Paris, France. 7. Department of Tumor Biology, Hôpital René Huguenin, Saint-Cloud, France. 8. Department of Medical Oncology, Hôpital René Huguenin, Saint-Cloud, France. 9. Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland.
Authors: Marylène Lejeune; Benoît Plancoulaine; Nicolas Elie; Ramon Bosch; Laia Fontoura; Izar de Villasante; Anna Korzyńska; Andrea Gras Navarro; Esther Sauras Colón; Carlos López Journal: Histochem Cell Biol Date: 2021-08-12 Impact factor: 4.304